BeyondSpring
必扬医药
BeyondSpring
Biotech/Healthcare
Biyang Pharmaceutical has completed a Series A financing round of nearly RMB 200 million. The funds will be used for the R&D of new drugs in the ophthalmology and oncology fields, improving R&D efficiency and enriching its pipeline.
Latest round: Series A (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-07-30
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.